SynthesisMediators of inflammation2026
The Predictive Role of Biomarkers for Leprosy Prophylaxis in Contacts of Patients Who Are Indices of the Disease: A Systematic Review of the Literature.
Synthesis in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- The Predictive Role of Biomarkers for Leprosy Prophylaxis in Contacts of Patients Who Are Indices of the Disease: A Systematic Review of the Literature.Mediators of inflammation · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leprosy continues to be an important public health problem, particularly in endemic regions such as Brazil, India, and Indonesia. Household contacts of multibacillary (MB) patients represent a high-risk group for subclinical infection due to prolonged exposure and high bacillary load. Host biomarkers have emerged as promising tools for identifying early infections and guiding prophylactic interventions. This systematic review aimed to identify and synthesize evidence on inflammatory and immune biomarkers associated with susceptibility to leprosy and disease progression among contacts of index cases, evaluating their potential predictive and diagnostic value. The study followed the Preferred Reporting Items for Systematic Reviews (PRISMA) 2020 guidelines and was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD420251111469). We searched CAPES, SciELO, PubMed, ScienceDirect, EMBASE, Scopus, and EBSCO databases for original studies published between 2012 and 2025, with no language restrictions. Two review authors independently selected studies using the Rayyan software, and methodological quality was assessed using the ROBIS tool. The biomarkers most frequently investigated in the studies were particularly tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-10, which play regulatory roles in the host. Elevated levels of TNF-α, interferon-γ (IFN-γ), IL-6, and IL-4 were associated with a higher risk of subclinical infection among contacts of MB patients, indicating a polyfunctional immune profile. On the other hand, paucibacillary (PB) contacts exhibited lower cytokine activation, suggesting partial protection. Additional promising markers included anti-Mce1A, PGL-I IgM, and CCL4, detected primarily by enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) methods. In summary, inflammatory and immune biomarkers-especially TNF-α, IL-10, IFN-γ, and anti-Mce1A-demonstrate potential as predictive indicators of subclinical leprosy infection. Their combined use may increase risk stratification and allow early therapeutic intervention in endemic settings. However, longitudinal validation studies are required prior to clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.